What is the Mayo classification of ulcerative colitis and how is it used to determine treatment?

Mayo Classification of Ulcerative Colitis

The Mayo Score is a 0-12 point composite scoring system comprising four components (stool frequency, rectal bleeding, physician's global assessment, and endoscopic findings), each scored 0-3, and is the most widely used tool in both clinical trials and practice to assess disease activity and guide treatment decisions in ulcerative colitis. 1, 2

Components of the Mayo Score

The Mayo Score evaluates four distinct parameters, each contributing 0-3 points 1:

• Stool frequency subscore: Assesses the number of bowel movements relative to normal 2
• Rectal bleeding subscore: Evaluates the presence and severity of blood in stool 2
• Physician's global assessment subscore: Incorporates the clinician's overall impression of disease activity 2
• Endoscopic subscore: Grades mucosal appearance from 0 (normal/inactive) to 3 (severe disease with spontaneous bleeding and ulcerations) 1, 2

Disease Activity Classification Using Mayo Score

The Mayo Score stratifies disease severity into clinically meaningful categories 1:

• Mild disease: Generally corresponds to lower Mayo scores
• Moderate disease: Intermediate Mayo scores (clinical trials typically enroll patients with Mayo 6-12) 3
• Severe disease: Higher Mayo scores, particularly with endoscopic subscore of 2-3 3

Clinical Definitions for Treatment Response

Clinical remission is defined as a total Mayo score ≤2 with no individual subscore >1, representing the primary treatment target 2, 1

Clinical response requires a reduction of baseline Mayo score by ≥3 points AND a decrease of ≥30% from baseline, with either a decrease of at least 1 point on the rectal bleeding subscale OR an absolute rectal bleeding score of 0 or 1 2, 4

Mucosal healing (endoscopic improvement) is defined as an endoscopic subscore of ≤1, which has prognostic significance for long-term outcomes 2, 3

The Partial Mayo Score

When endoscopy is not immediately available, the partial Mayo score (maximum 9 points) uses only the three non-invasive components, excluding the endoscopic subscore 5, 1:

• The British Society of Gastroenterology recommends using the partial Mayo score for monitoring remission in combination with biomarkers like fecal calprotectin and C-reactive protein 5, 2
• The partial Mayo score correlates well with patient perceptions of response to therapy and performs similarly to the full Mayo score in identifying clinical response 5, 6

How Mayo Score Determines Treatment Strategy

For patients with Mayo endoscopic subscore 2-3 (moderate-to-severe disease), higher or intermediate efficacy advanced therapies should be used rather than lower efficacy options, including TNF antagonists, JAK inhibitors, IL-12/23 antagonists, or S1P modulators 3

Treatment escalation decisions follow this algorithm 3:

• Assess symptomatic response within 3 months of initiating advanced therapy
• Perform endoscopic reassessment at 6-12 months to evaluate for endoscopic improvement/remission
• Consider extended induction or dose escalation for patients with Mayo 3 disease showing inadequate initial response

Sustained Response and Remission

Long-term treatment success is measured by sustained outcomes 4:

• Sustained response: Clinical response at both Week 8 and Week 30 (or through Week 54 in longer studies) 4
• Sustained remission: Clinical remission at both Week 8 and Week 30 (or through Week 54) 4, 7
• In infliximab trials, sustained remission rates ranged from 20-26% compared to 7-8% with placebo at Week 54 4

Corticosteroid-Free Remission

Among patients on corticosteroids at baseline, 21-23% in infliximab treatment groups achieved clinical remission while discontinuing corticosteroids by Week 30-54, compared to 3-10% in placebo groups 4

Common Pitfalls and Caveats

Endoscopic appearance may significantly underestimate true disease extent, particularly in quiescent ulcerative colitis, and should be confirmed by segmental biopsies 5

There is wide variation in interpretation of endoscopic disease activity between observers, which can affect Mayo endoscopic subscore reliability 5

Patients may achieve clinical remission (symptomatic improvement) while still having Mayo 3 endoscopic disease, requiring continued therapy escalation rather than assuming adequate treatment 3

The Mayo Score considers only the most severely affected colonic segment, which may miss improvements in overall disease burden—a limitation when assessing treatment response 8

Multimodal Monitoring Approach

The British Society of Gastroenterology recommends combining multiple assessment modalities 5:

• Clinical index (partial Mayo or Simple Clinical Colitis Activity Index)
• Laboratory markers (hemoglobin, C-reactive protein, fecal calprotectin)
• Intestinal ultrasound (if available)
• Colonoscopy or sigmoidoscopy with histology at appropriate intervals